Zacks Investment Research on MSN

Cytokinetics wins EU approval for cardiovascular drug Myqorzo

Cytokinetics, Incorporated CYTK announced that the European Commission (EC) has approved Myqorzo (aficamten), 5 mg, 10 mg, 15 ...
The Manila Times

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

MYQORZO was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms, and by the China National Medical ...